DuoPlavin

Selected form

Method of action: Antithrombotic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of DuoPlavin

Quick Facts

Property	Description
Active Ingredients	Acetylsalicylic Acid (ASA), Clopidogrel
Form	Film-coated tablet
Pharmacological Class	Antiplatelet medicines
Common Use	Prevention of atherothrombotic events
Origin	Synthetic

What Type of Medicine is DuoPlavin?

DuoPlavin is defined as a fixed-dose combination medicinal product intended for oral use, supplied as a single film-coated tablet. This synthetic pharmaceutical entity is a prescription-only medicine that belongs to the high-level pharmacological group of antiplatelet medicines, specifically designed to inhibit the aggregation of platelets. The product is clinically recognized for its role in secondary prevention strategies, a feature supported by comprehensive pharmacological studies.

What is DuoPlavin Made Of? (Composition and Combination Strategy)

The medicine is composed of two primary active ingredients: Acetylsalicylic Acid (ASA) and Clopidogrel. This composition provides dual antiplatelet therapy (DAPT), utilizing two distinct synthetic compounds to maximize anti-clotting efficacy. The formulation's primary differentiating factor is its fixed-dose structure, which is intended to increase patient adherence compared to prescribing the same two agents as separate tablets. ASA works by inhibiting an enzyme that reduces the production of the clot-promoting agent thromboxane, while Clopidogrel acts as a P2Y12 platelet inhibitor, blocking a key receptor on the surface of platelets.

What is the General Purpose of This Dual Antiplatelet Agent?

The overarching goal of DuoPlavin is the prevention of atherothrombotic events caused by blood clots forming inside arteries narrowed by existing disease. By robustly inhibiting the ability of platelets to aggregate, the drug helps maintain unobstructed blood flow. The medicine provides sustained protection and is typically utilized for the continuation of therapy in adult patients, ensuring consistent delivery of the dual antiplatelet regimen required in a typical use scenario.

Regulatory References

What side effects are possible with DuoPlavin ?

Possible Side Effects and Safety Information

The officially documented safety profile for this medicine centers on its function as a dual antiplatelet agent, with bleeding reactions being the most common adverse characteristic reported across regulatory documents. These events are classified by frequency and categorized according to the affected System-Organ Classes.

Frequency and Organ Systems

Side effects are classified using standard regulatory frequency categories. Common reactions (affecting up to 1 in 10 people) include minor bleeding events such as haematoma, epistaxis (nosebleeds), bruising, and bleeding at the puncture site. Gastrointestinal disorders are also frequently noted, including diarrhoea, abdominal pain, and dyspepsia (heartburn).

Serious Adverse Reactions and Safety Constraints

While the majority of side effects are categorized as common, the regulatory documentation explicitly notes the risk of life-threatening and fatal bleeding, including severe gastrointestinal or intracranial haemorrhage. A very rare ( <1/10,000) but serious adverse reaction is Thrombotic Thrombocytopenic Purpura (TTP), a condition affecting the blood and nervous system that requires immediate attention.

The regulatory labeling defines specific constraints for use. The medicine is Contraindicated in individuals with active pathological bleeding (e.g., peptic ulcer) and in those with severe hepatic impairment or severe renal impairment (creatinine clearance <30 ml/min). Furthermore, regulatory notes indicate that the risk of bleeding may require particular monitoring during the initial weeks of treatment.

Population-Specific Safety

Due to the increased risk of major bleeding documented in the regulatory texts, specific caution is required for patients with a history of recent transient ischaemic attack or stroke.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents indicate that specific information regarding overdose with the fixed combination product DuoPlavin is limited. Therefore, the overdose profile is based on the known effects of the two component substances: clopidogrel and acetylsalicylic acid (ASA).

Documented Overdose Manifestations

Component	Signs of Overdose	Risk/Complication
Clopidogrel	Prolonged bleeding time	Bleeding complications (e.g., hemorrhage)
ASA	Tinnitus (ringing in the ears), nausea, vomiting, drowsiness, confusion, rapid breathing	Systemic toxicity and potentially serious effects

Required Emergency Action

Immediately seek emergency medical attention if any signs or symptoms of overdose are observed. This is essential for both components, as serious bleeding or systemic toxicity may occur.

For Clopidogrel Overdose: If prolonged bleeding is observed and prompt reversal is required by medical professionals, a platelet transfusion may be considered. No known antidote exists for the pharmacological activity of clopidogrel.
For ASA Overdose: Management generally involves supportive measures to address systemic toxicity and may include the use of activated charcoal and procedures to accelerate elimination, as determined by a healthcare provider.

Therapeutic Uses of DuoPlavin

What DuoPlavin Treats: Main Uses and Benefits

DuoPlavin is primarily utilized within the critical domain of secondary prevention for patients who have experienced a life-threatening vascular event. The core benefit provided plays a role in managing symptoms that may become intense or disruptive by maintaining effective dual antiplatelet protection.

DuoPlavin is a fixed-dose combination indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid as separate tablets. This medicine is commonly used across conditions presenting with acute episodes.

Protection and Therapeutic Continuity

This medication is central to the management of patients following a diagnosis of Acute Coronary Syndrome (ACS). The therapeutic domain helps address the underlying risk of severe symptoms caused by atherothrombosis, and contributes to easing the overall symptom load associated with future events. It is applied across domains where additional symptomatic support is needed, specifically following heart attack (Myocardial Infarction), Unstable Angina, or after procedures such as coronary stenting.

The fixed-dose format assists with patient adherence to the mandatory dual antiplatelet regimen. This therapeutic strategy is relevant in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing the distress of potentially facing another vascular event.

Quick Fact Block

Property	Description
Quick Fact: Focus	Management of recurrent Acute Coronary Syndrome and high vascular risk
Symptom Domain	Symptoms related to heightened physiological activity (atherothrombosis)
Clinical Context	Post-Acute Coronary Syndrome and Post-Coronary Stenting
Patient Benefit	Supports general well-being during symptomatic phases

Regulatory References

EMA therapeutic overview

Eligibility and Restrictions for Use

DuoPlavin is officially indicated for adult patients continuing dual antiplatelet therapy who are already stabilized on clopidogrel and acetylsalicylic acid (ASA) as separate medicines.

Contraindications (Must Not Use)

Use of DuoPlavin is contraindicated and must be avoided in several patient groups, as defined by regulatory authorities. These absolute exclusions include individuals with active pathological bleeding (such as a bleeding peptic ulcer or intracranial haemorrhage) and patients diagnosed with severe hepatic impairment or severe renal impairment (creatinine clearance <30 mL/min). Hypersensitivity to either active component, any excipients, or to Non-Steroidal Anti-inflammatory Drugs (NSAIDs) also constitutes a contraindication. Furthermore, the medicine is formally contraindicated during the third trimester of pregnancy.

Restricted and Non-Recommended Use

DuoPlavin is not recommended for children and adolescents under 18 years old, as its safety and efficacy have not been established in the pediatric population. Use requires special caution or is subject to restrictions in patients with mild to moderate hepatic or renal disease due to limited therapeutic experience. Caution is also advised for patients with a history of peptic ulcer or a recent transient ischaemic attack or stroke.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for DuoPlavin (Clopidogrel and Acetylsalicylic Acid, ASA) as specified in governmental prescribing information, covering pharmacokinetic changes and pharmacodynamic effects.

Formal Contraindicated Combinations and Exposure Restrictions

Co-administration with certain medicinal products is formally restricted, primarily due to an elevated risk of bleeding or compromised therapeutic action:

Oral Anticoagulants: Concomitant use with oral anticoagulants, such as Warfarin, is not recommended due to a documented increase in the intensity and risk of hemorrhage.
Systemic NSAIDs: Combining with systemic Non-Steroidal Anti-Inflammatory Drugs is discouraged due to a heightened risk of gastrointestinal damage and bleeding.
CYP2C19 Inhibitors: Use with strong inhibitors, such as Omeprazole or Esomeprazole, is avoided because it reduces the plasma concentration of Clopidogrel's active metabolite, diminishing its antiplatelet effect.
Opioids: Administration of opioids, such as Morphine, may result in decreased exposure to the active metabolite, reducing antiplatelet activity.
Alcohol: Consumption of alcohol is documented to increase the risk of gastrointestinal bleeding and mucosal damage due to the ASA component.

Procedural and Population Constraints

Official labeling includes mandatory timing constraints and population-specific restrictions related to interactions:

Elective Surgery: The medicine must be discontinued 5 to 7 days prior to elective surgical procedures to mitigate the risk of bleeding.
Severe Hepatic Impairment: DuoPlavin is contraindicated in patients with severe hepatic impairment, a restriction related to drug clearance and associated hemorrhage risk.

Mechanism of Action

Dual Irreversible Blockade of Platelet Activation

DuoPlavin's mechanism relies on two distinct, permanent molecular blocks within the circulating platelet. The first component irreversibly inhibits the COX-1 enzyme, halting the synthesis of the pro-aggregatory mediator TXA2. Simultaneously, the second component irreversibly antagonizes the P2Y12 receptor, preventing the platelet from activating in response to ADP signaling. This combined action achieves a systemic and sustained attenuation of primary hemostasis that lasts for the lifespan of the treated platelet.

Synergy Through Complementary Pathway Inhibition

This mechanism is based on complementary pathway inhibition, a synergistic strategy where the two active ingredients target different, yet essential, biochemical cascades. By blocking both the TXA2 generation pathway and the ADP signal transduction pathway, the drug leads to a combined suppression of the platelet's ability to transition into its activated, clumping state, reflecting the synergistic targeting of two distinct pathways. This dual suppression directly prevents the activation of the final common pathway (GPIIb/IIIa receptor complex), leading to specific physiological adjustments in clotting capability.

Mechanistic Variability Linked to Metabolic Constraint

The action of Clopidogrel's contribution to this dual mechanism is subject to a pharmacogenetic constraint because it requires metabolic activation. Clopidogrel is an inactive prodrug that must be converted by the liver enzyme CYP2C19 into its active form before it can bind to the P2Y12 receptor. Genetic variations in the CYP2C19 enzyme can reduce the formation of the active metabolite, resulting in reduced P2Y12 antagonism and potential variability in the antiplatelet physiological effect.

Dosage and Administration Information

Official Administration Guidelines

DuoPlavin is administered exclusively by the oral route as a fixed-dose combination film-coated tablet. The medicine is specifically designated for the continuation of therapy in adult patients who have already completed the initial treatment phase with clopidogrel and acetylsalicylic acid (ASA) given as separate medicines.

Instruction	Detail
Dosing Schedule	One tablet taken once daily. Available strengths are 75 mg clopidogrel with 75 mg ASA or 100 mg ASA.
Timing & Food	The tablet may be taken with or without food.
Duration (Non-STEMI ACS/UA)	Typically continued for up to 12 months.
Duration (STEMI)	Continued for a minimum of four weeks.
Special Populations	Not recommended for use in the pediatric population (< 18 years). Contraindicated in patients with severe hepatic impairment.

This regimen is established to ensure consistent delivery of the dual antiplatelet components.

Missed Dose Protocol

A defined protocol governs the necessary action following a missed dose to maintain the therapeutic regimen:

Missed Timeframe	Required Action (Do Not Double Dose)
Less than 12 hours	Take the dose immediately, then resume the regular scheduled time.
More than 12 hours	Skip the missed dose and take only the next dose at the regular scheduled time.

These administration rules are provided to offer clear steps for sustaining therapeutic continuity.

Recent Clinical Evidence

Research evidence / Overview of studies for DuoPlavin

Evidence for the Fixed-Dose Combination

Research for the fixed-dose DuoPlavin tablet was designed to examine whether the single pill is comparable to taking the same two active ingredients—Clopidogrel and Acetylsalicylic Acid (ASA)—as two separate tablets. These research scenarios included bioequivalence studies and non-inferiority trials.

Studies monitored the antiplatelet effect and drug levels in the bloodstream, and the findings describe patterns that were comparable to those observed with the separate tablets. Furthermore, research has explored patient adherence, and some studies reported that measures of adherence and persistence were associated with the use of the single, fixed-dose tablet over defined time intervals compared to taking the two pills separately.

Evidence for the Dual Antiplatelet Regimen in Acute Coronary Syndrome (ACS)

The evidence supporting the two-drug regimen (Clopidogrel plus ASA) originates from large-scale, multinational Randomized Controlled Trials (RCTs). These pivotal trials were evaluated in adult patients presenting with conditions characterized by acute or disruptive episodes, such as unstable angina or a heart attack (Acute Coronary Syndrome, or ACS).

Studies monitored these patients over periods ranging from several months up to a year. The findings describe group patterns and observed rates of composite vascular events, including non-fatal heart attack, non-fatal stroke, and cardiovascular death, that were associated with the dual regimen.

Key research notes that the fixed-dose DuoPlavin tablet was not used in these initial, large-scale RCTs that established the core evidence for the dual therapy. The evidence for DuoPlavin is contextualized by the established research for the two components taken separately, combined with the successful comparability studies of the single tablet itself.

Synthesis of Evidence Gaps and Areas of Uncertainty

A key finding is that comparative evidence is lacking from new, dedicated, large-scale RCTs that use the fixed-dose combination to measure major clinical events directly against a placebo or single-agent control. Additionally, follow-up durations were limited in some studies, meaning that long-term effects are not fully established for the dual regimen in all specific contexts. Subgroup findings are uncertain for specific conditions, such as severe hepatic or renal disease, where dedicated evidence is minimal.

How should DuoPlavin be stored and disposed of?

How to Store and Dispose of DuoPlavin

Storage and disposal of DuoPlavin (clopidogrel and acetylsalicylic acid) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C (77°F).
Container	Must be kept in the original container to protect the tablets from moisture.
Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired DuoPlavin must be disposed of according to official guidelines to protect the environment. The medicine must not be thrown away with household trash or via wastewater. For proper disposal, unused product should be returned to a pharmacist or collected via a local pharmaceutical waste scheme.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.